Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives

Simply Wall St.

Yesterday

Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614858228"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614858228\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614858228?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-27 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614858228","market":"nz","top_or_hot":-1,"title":"Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives","media":"Simply Wall St.","content":"<div>\n<p>Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinogen Medical H1 2026 Wider A$17.9m TTM Loss Reinforces Bearish Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-27 16:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TTM","symbol_name":"塔塔汽车","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","article_id":"2614858228","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-h1-2026-wider-a179m-ttm-loss-reinforces-be","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614858228","pubTimestamp":1772181827,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TTM":"塔塔汽车","BK7067":"生物科技","BK7508":"医药生物股","BK4523":"印度概念","BK4099":"汽车制造商","ACW.AU":"ACTINOGEN MEDICAL LTD"},"translate_title":"Actinogen Medical 2026年上半年TTM亏损1790万澳元强化了看跌叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACW.AU":1,"TTM":1.5},"content_text":"Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing how much further margin pressure they are comfortable with as the story plays out. See our full analysis for Actinogen Medical. With the latest figures on the table, the next step is to set these margins and losses against the most common narratives around Actinogen Medical to see which views hold up and which ones the numbers call into question. Curious how numbers become stories that shape markets? Explore Community Narratives ASX:ACW Revenue & Expenses Breakdown as at Feb 2026 AdvertisementLosses widen to A$17.9 million over the last year  Over the trailing twelve months, Actinogen booked a net income loss of A$17.9 million on A$7.4 million of revenue, compared with half year losses of A$1.5 million in H2 2024, A$8.2 million in H1 2025 and A$6.6 million in H2 2025. This keeps the story firmly about funding ongoing operations rather than any path to profitability in these numbers. Bears highlight that ACW is unprofitable and that losses have grown at about 22.1% per year over the past five years, and the trailing data lines up with that concern as net income losses stepped up from A$9.7 million in the period ending H1 2025 to A$14.7 million in the period ending H2 2025 and then to A$17.9 million in the latest twelve month window.\n     Critics also point out that ACW is forecast to remain loss making for at least the next three years, and the current A$0.0058 loss per share over the last twelve months does not give any evidence of a break in that pattern yet. With the share price at A$0.041, the market is currently valuing the company despite these A$17.9 million trailing losses. This is exactly what cautious investors focus on when they say the risk side of the story is front and center.    On this set of numbers, skeptics argue the bigger A$17.9 million annual loss is a stress test for anyone treating ACW as a high risk biotech rather than a near term earnings story. 🐻 Actinogen Medical Bear Case Revenue swings from A$9.0 million to zero and back again  Looking at the half year pattern, revenue moved from A$9.0 million in H2 2024 to A$0 in H1 2025, then to A$5.5 million in H2 2025 and A$7.4 million over the last twelve months. This points to a business where the top line can shift sharply between periods rather than follow a smooth curve. General market opinion on early stage biotech stories often leans on the idea that patchy revenue is less important than funding runway and clinical progress, and these figures fit that pattern by showing swings in revenue while losses stayed large, with A$8.2 million, A$6.6 million and A$17.9 million net income losses tied to those last three reported periods.\n     What stands out is that even when revenue was A$9.0 million in H2 2024, the company still recorded a A$1.5 million loss for that half, which suggests recent profitability has not simply been about one weak revenue period. For you as an investor, this mix of lumpy revenue and persistent losses means the headline A$7.4 million trailing revenue figure only really makes sense when you set it against how much cash the company is spending to keep its programs moving.    P/S of 19.3x is above industry and peers  On valuation multiples, ACW trades on a P/S of 19.3x, compared with about 16.5x for the broader Australian biotech industry and 9.7x for its peer group, so the market is currently applying a richer revenue multiple despite the A$17.9 million trailing loss. Bears argue that paying a premium P/S multiple for shrinking or pressured financials is hard to justify, and here the data lean their way with revenue expected to decline at around 42.6% per year over the next three years and earnings forecast to fall by about 37.2% per year while the company is still not expected to be profitable.\n     This combination of higher than average P/S and forecast revenue and earnings declines is exactly what cautious holders point to when they say the balance of identified risks outweighs any upside case in the supplied numbers. At the same time, with no identified rewards in the data, anyone looking at the A$0.041 share price has to decide whether that 19.3x P/S and ongoing losses line up with their own tolerance for this kind of biotech exposure. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Actinogen Medical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If this all sounds cautious, that is exactly why it is worth checking the numbers yourself and forming your own view promptly. To see what risks others are focused on, review the 2 important warning signs tied to this company. See What Else Is Out There Actinogen Medical is facing A$17.9 million in trailing losses, patchy revenue, premium P/S multiples and no identified rewards in the supplied data. If that mix of larger losses, lumpy revenue and higher valuation feels a bit too punchy for your risk comfort, take a look at our 8 resilient stocks with low risk scores to quickly compare ideas that put balance and resilience ahead of speculation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}